Allogeneic transplant for older AML patients - who, when and how
The future of AML and MDS diagnosis and treatment
Stéphane de Botton
How is the landscape of Hodgkin lymphoma therapy changing?
Ibrutinib in treatment for refractory or relapsed CLL
New strategies in AML: checkpoint inhibitors combined with T-cell engagers